Sangamo Therapeutics, Inc. SGMO 深 沪
交易中 04-01 12:08:41 美东时间
0.2822
+0.035
+14.30%
华盛通- 最 高0.2823
- 今 开0.2373
- 成交量 491.19万股
- 最 低 0.2353
- 昨 收 0.2469
- 总市值 1.17亿
- 52周最高 0.84
- 市盈率 静 --
- 换手率 1.19%
- 52周最低 0.205
- 委 比 -43.20%
- 总股本 4.14亿
- 历史最高 27.50
- 量 比 1.19
- 振 幅 19.04%
- 历史最低 0.205
- 每 手 1
- 风险率 0.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares moved upwards by 138.8% t...
03-31 20:05
Sangamo Therapeutics Q4 EPS $(0.11) Misses $(0.06) Estimate, Sales $14.200M Miss $16.475M Estimate
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.06) by 83.33 percent. This is unchanged from the same period last year. The company
03-31 04:02
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Sangamo Therapeutics will release Q4 earnings on March 30. Analysts predict a quarterly loss of 5 cents per share and revenue of $40.25 million.
03-30 16:07
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
Sangamo Therapeutics scheduled the release of its fourth quarter and full year 2025 financial results after the market close on March 30, 2026. A conference call will be held at 4:30 p.m. Eastern on the same date, open to the public. Participants can register via the provided link and access the call either by dialing in or using the dial-out option. The live webcast and replay will be accessible on the company's website.
03-19 20:03
Sangamo Therapeutics Advances Rolling Submission Of Its Biologics License Application To FDA For Accelerated Approval Of Isaralgagene Civaparvovec
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a
03-09 20:17
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Sangamo Therapeutics has advanced the rolling submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The submission includes preclinical and clinical modules, with the antibody assay companion diagnostic also accepted by the FDA. Data from the Phase 1/2 STAAR study demonstrated positive mean annualized eGFR slope at 52 weeks, supporting ...
03-09 12:05
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
Sangamo Biosciences launches dilutive February 2026 financing
An update from Sangamo Biosciences ( ($SGMO) ) is now available. On February 3,...
02-04 21:59
Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor
Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor Sangamo Therapeutics Inc. hat am 3. Februar 2026 die Präsentation klinischer Daten aus der zulassungsrelevanten Phase-1/2-STAAR-Studie zu Isaralgagene Civaparvovec (ST-920), einem firmeneigenen G
02-04 05:09
